Mobilion Systems, a US-based biomedical equipment spinout of Pacific Northwest National Laboratory (PNNL), completed a $60m series C round yesterday featuring diagnostics services provider Agilent Technologies.

Investment firm D1 Capital Partners led the round, which also attracted IP Group, aMoon, Hostplus and Cultivation Capital.

Founded in 2015, Mobilion develops analytical instruments to separate, identify and analyse proteins and examine molecules. The technology can be used for early disease detection and to develop treatments that target the root causes of health conditions.

The funding will allow Mobilion to scale the commercialisation of its inaugural product, Mobie, which is marketed at biopharmaceutical clients, and to progress the development of additional products aimed at the bioprocessing and multiomic biomarker discovery markets.

The company had previously secured $35m in an August 2020 series B round led by aMoon and backed by Agilent, IP Group, Hostplus, Cultivation Capital and undisclosed existing investors.

Agilent had already led a $15.4m series A round for Mobilion in late 2019 that included IP Group, Hostplus, Cultivation Capital and iSelect Fund.

The original version of this article appeared on our sister site, Global University Venturing.

Mobilion Systems, a US-based biomedical equipment spinout of Pacific Northwest National Laboratory (PNNL), completed a $60m series C round yesterday featuring commercialisation firm IP Group.
D1 Capital Partners led the round, which also attracted diagnostics services provider Agilent Technologies, aMoon, Hostplus and Cultivation Capital.
Founded in 2015, Mobilion develops analytical instruments to separate, identify and analyse proteins and examine molecules. The technology can be used for early disease detection and to develop treatments that target the root causes of conditions.
The series C funding will allow Mobilion to scale the commercialisation of its inaugural product, Mobie, which is marketed at biopharmaceutical clients and to progress the development of additional products aimed at the bioprocessing and multiomic biomarker discovery markets.
The spinout previously secured $35m in a series B round also backed by IP Group in August 2020. The round was led by aMoon and also attracted Agilent Technologies, Hostplus, Cultivation Capital and undisclosed existing investors.
IP Group had already participated in a $15.4m series A round in 2019 that was led by Agilent. Hostplus, Cultivation Capital and iSelect Fund also took part in that transaction.